Juan Zhang
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy.
Journal: Frontiers in oncology
Published: May 12, 2026
New Dimensions in Diabetic Kidney Disease Research: Advanced Organoids and Organs-on-a-Chip.
Journal: BME frontiers
Published: April 28, 2026
Valine-Alanine-Based Peptidomimetic Linker for Antibody-Drug Conjugates.
Journal: Journal of medicinal chemistry
Published: January 19, 2026
β-glucuronidase-triggered ortho-hydroxyl-mediated cyclization strategy for the efficient delivery of phenolic payloads in antibody-drug conjugates.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: December 25, 2025
Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance.
Journal: Journal for immunotherapy of cancer
Published: December 01, 2025
Activated circulating T follicular helper 17 cells positively correlated with anti-HBV humoral immunity in chronic hepatitis B patients.
Journal: Frontiers in microbiology
Published: September 18, 2025
Network toxicology and multi-omics analyses identify diagnostic genes and elucidate underlying mechanisms of 6PPDQ-induced hepatocellular carcinoma.
Journal: Environmental pollution (Barking, Essex : 1987)
Published: September 09, 2025
A Bifunctional Anti-PD-1/TGF-β Fusion Antibody Restores Antitumour Immunity and Remodels the Tumour Microenvironment.
Journal: International journal of molecular sciences
Published: July 11, 2025
Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody.
Journal: International immunopharmacology
Published: May 24, 2024
Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy.
Journal: Journal of hepatocellular carcinoma
Published: November 29, 2023
Site-specific Antibody-Nitric Oxide Conjugate HN02 Possesses Improved Antineoplastic and Safety Properties.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: November 14, 2023
Last Updated: 09/26/2026